Literature DB >> 32211114

Clinicopathologic significance and treatment of ASC-US in cervical cytology.

Asrar Mohammed Abdullah Abdulaziz1, Lu Liu1, Yu Sun1, Xuewu You1, Baoxia Cui1, Sai Han1, Youzhong Zhang1.   

Abstract

BACKGROUND: In China, cervical cancer is one of the most common gynecologic malignancies. Cervical cytology is an essential method for screening cervical cancer and cervical intraepithelial neoplasia (CIN), and the most common cytological abnormality result is atypical squamous cells of undetermined significance (ASC-US). Therefore, how to effectively deal with ASC-US cytology has become the focus of scholars.
OBJECTIVE: We aim to analyze the final histopathologic results, clinicopathologic significance and current rationale of ASC-US cytology.
METHODS: All patients with first ASC-US cytological reports who attended our gynecological outpatient clinic in Qilu Hospital of Shandong University during January 2010 to December 2015 were recruited to this study. The data were derived from clinical records and evaluated retrospectively. The results of age, High-Risk HPV (DNA) testing, colposcopy, and pathological outcomes were obtained. Directed biopsy was performed if there were any suspicious cervical lesions under colposcopy, while four quadrant biopsy and/or ECC were performed if no suspicious lesions were noted in colposcopies.
RESULTS: A total of 1246 patients diagnosed with ASC-US were involved in the final statistical analysis. Mean age of patients was 41.6 years and the age range between 40-49 years represented 38.52% of all ASC-US women in this study. All patients were evaluated for HPV (DNA) and positive percent for High-Risk HPV was (67.1%). According to the final histopathologic outcomes after ASC-US cytology, 15.6% and 1.1% of patients had ≥ CIN2+ and invasive carcinoma respectively. Patients with invasive carcinoma were associated with HPV16+ and HPV18+. The detection rate of ≥ CIN2+ among the ASC-US/High-Risk HPV+ group was (53.9%) with a negative-predictive-value (NPV) of 100%. Our findings showed that the final pathologic results of ≥ CIN2+ were consistent with colposcopy with a coincidence rate of (77%), and colposcopical impression sensitivity and specificity for ≥ CIN2+ was (91.1% and 96.1%) respectively.
CONCLUSION: women with ASC-US have a wide range of final pathologic results, and it can be the initial warning of high-grade CIN or cervical cancer. In China, HPV (DNA) testing triage is a useful shunting measure for ASC-US patients, and an immediate colposcopy is a consequential strategy for dealing with ASC-US cytology to increase the detection rate of high-grade cervical lesions or invasive cancer. IJCEP
Copyright © 2020.

Entities:  

Keywords:  ASC-US; CIN; HPV; biopsy; colposcopy

Year:  2020        PMID: 32211114      PMCID: PMC7061793     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

2.  Patients with epithelial cell abnormality in PAP smears: correlation of results with follow-up smears and cervical biopsies.

Authors:  Ilknur Çetinaslan Türkmen; Nuray Başsüllü; Pınar Korkmaz; Banu Günenç; Cem Murat Baykal; Nilgün Güdücü; Herman Işçı; Ilkkan Dünder; Gülen Bülbül Doğusoy
Journal:  Turk Patoloji Derg       Date:  2013

Review 3.  European guidelines for quality assurance in cervical histopathology.

Authors:  Johan Bulten; Reinard Horvat; Joe Jordan; Amanda Herbert; Helene Wiener; Marc Arbyn
Journal:  Acta Oncol       Date:  2011-02-11       Impact factor: 4.089

4.  Atypical squamous cells of undetermined significance in patients with HPV positive DNA testing and correlation with disease progression by age group: an institutional experience.

Authors:  Erika F Rodriguez; Jordan P Reynolds; Sarah M Jenkins; Stephanie M Winter; Michael R Henry; Aziza Nassar
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

5.  Follow-up of women with ASCUS in Chile.

Authors:  López Fanny; Quezada Orlando; Barrios Trinidad; López Estefanía
Journal:  Diagn Cytopathol       Date:  2011-04       Impact factor: 1.582

6.  Significance of atypical squamous cells of undetermined significance on ThinPrep papanicolaou smears.

Authors:  G H Eltabbakh; J N Lipman; S L Mount; A Morgan
Journal:  Gynecol Oncol       Date:  2000-10       Impact factor: 5.482

7.  Results of Further Diagnostic Procedures Among Patients with Cytological Characteristics of Minor Changes on Pap Smears.

Authors:  Joanna Kacperczyk; Paweł Bartnik; Ewa Romejko-Wolniewicz; Katarzyna Jalinik
Journal:  Anticancer Res       Date:  2016-03       Impact factor: 2.480

8.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance, after six months delay: a three-year experience in an Iranian university hospital.

Authors:  Fariba Yarandi; Hadi Shojaei; Zahra Eftekhar; Narges Izadi-Mood
Journal:  Aust N Z J Obstet Gynaecol       Date:  2009-04       Impact factor: 2.100

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.

Authors:  Raquel Ibáñez; Judit Moreno-Crespi; Montserrat Sardà; Josefina Autonell; Montserrat Fibla; Cristina Gutiérrez; Belen Lloveras; María Alejo; Isabel Català; Francesc Alameda; Miquel Casas; F Xavier Bosch; Silvia de Sanjosé
Journal:  BMC Infect Dis       Date:  2012-01-26       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.